Juvenile idiopathic arthritis

Table 4 Biologic agents used in the treatment of juvenile idiopathic arthritis

Drug	Target	FDA approval for JIA	Administration	Dosage
Etanercept	TNF-α	Polyarticular JIA ages 2 yr and older	Subcutaneous injection	0.8 mg/kg per dose once a week, maximum 50 mg/dose
Adalimumab	TNF-α	Polyarticular JIA ages 4 yr and older	Subcutaneous injection	24 mg/m2 every 2 wk, maximum 40 mg/dose
Infliximab	TNF-α	No	Intravenous infusion	6-10 mg/kg per dose week 0, 2 and 6; then every 4 to 8 wk
Anakinra	IL-1	No	Subcutaneous injection	1-2 mg/kg per day, maximum 100 mg/dose
Canakinumab	IL-1	Systemic-onset JIA ages 2 yr and older	Subcutaneous injection	2-4 mg/kg every 4 wk
Rilonacept	IL-1	No	Subcutaneous injection	2.2-4.4 mg/kg once a week
Abatacept	Cytotoxic T-lymphocyte- associated antigen 4	Polyarticular JIA ages 6 yr and older	Intravenous infusion	10 mg/kg week 0, 2 and 4; then every 4 wk, maximum 1000 mg/dose
Rituximab	CD20	No	Intravenous infusion	750 mg/m2; two doses 2 wk apart or 375 mg/m2; four doses, weekly × 4, maximum 1000 mg/dose
Tocilizumab	IL-6	Polyarticular JIA ages 2 yr and older	Intravenous infusion	8 -12 mg/kg every 2 wk

TNF-α: Tumor necrosis factor-alpha; IL-6: Interleukin-6; JIA: Juvenile idiopathic arthritis.